Home / Market News / $FHTX
benzinga Corporate Catalyst Impact 85/100 ● negative

Foghorn Therapeutics Pivots Pipeline after Ending Eli Lilly Deal

Oct 1, 2026, 4:17 PM UTC · Primary ticker $FHTX

Foghorn Therapeutics is ending its collaboration with Eli Lilly on FHD-909 and other programs after reviewing Phase 1 data, leading to a significant pipeline reprioritization and a 40% workforce reduction. This strategic shift aims to extend the company's cash runway into H2 2029 by focusing on wholly-owned assets, but signals a major setback for its partnered programs.

Foghorn Therapeutics (FHTX) announced the termination of its collaboration with Eli Lilly (LLY) for the FHD-909 program and other discovery efforts, following disappointing Phase 1 data for FHD-909. This is a significant negative catalyst for FHTX, as the Lilly partnership was a key validation and funding source. In response, Foghorn is pivoting its pipeline to wholly-owned assets, including an EP300 degrader, and implementing a 40% workforce reduction to extend its cash runway. While this move aims to preserve capital and focus on promising internal programs, the immediate impact is a loss of a major partner and a setback in its lead partnered program, leading to a sharp decline in stock price. For LLY, the impact is minimal given its vast pipeline. The long-term success for FHTX now hinges entirely on its ability to rapidly advance its wholly-owned pipeline, particularly the EP300 degrader, towards clinical trials and positive data.

$FHTX negative Ended key collaboration, pipeline setback, workforce reduction
$LLY neutral Ended collaboration, minor impact on large pharma
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.